Samsara BioCapital, LLC

CIK 0001744967 · PALO ALTO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source

Samsara BioCapital, LLC reported 24 positions worth $1.22B as of June 30, 2026 (13F filed August 14, 2026). Largest holding: SRRK (31.2%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$1.22B
2026 Q2
Positions
24
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
90.5%
Est. Net Flow (Q)
2026 Q2
10 / 24 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1SRRK SCHOLAR ROCK HLDG CORP SH$379.4M31.16%6,897,652
2ALMS ALUMIS INC SH$178.6M14.67%6,345,219
3MLYS MINERALYS THERAPEUTICS INC SH$158.4M13.01%5,871,018
4SEPN SEPTERNA INC SH$105.5M8.66%3,149,128
5ALMR ALAMAR BIOSCIENCES INC SH$67.2M5.52%2,480,310
6NGNE NEUROGENE INC SH$54.0M4.44%1,717,127
7KLRS KALARIS THERAPEUTICS INC SH$52.4M4.31%12,881,175
8SGP SPYGLASS PHARMA INC SH$47.0M3.86%2,109,953
9STRO SUTRO BIOPHARMA INC SH$35.3M2.90%1,062,872
10IVA INVENTIVA SA SH$23.9M1.96%6,314,805

The free plan shows the top 10 positions. The remaining 14 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Samsara BioCapital, LLC hold as of Q2 2026?

Samsara BioCapital, LLC reported 24 positions worth $1.22B in its Q2 2026 13F filing. Largest positions: SRRK (31.2%), ALMS (14.7%), MLYS (13.0%), SEPN (8.7%) and ALMR (5.5%).

What did Samsara BioCapital, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Samsara BioCapital, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.